Genentech Inc.’s third-quarter profit rose 2% to...

Genentech Inc.’s third-quarter profit rose 2% to $5.3 million. Revenue advanced 83% to $245.3 million. The San Francisco biotechnology company had predicted a disappointing performance because of slower-than-expected sales of its heart drug TPA, which it has decided to stop producing until 1989.